Your browser doesn't support javascript.
loading
Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes, D J; Obenchain, R L; Barber, B L; Smith, A; McDonald, M; Broderick, T M; Runyon, J P; Shimshak, T M; Schneider, J F; Hattemer, C R; Roth, E M; Whang, D D; Cocks, D; Abbottsmith, C W.
Affiliation
  • Kereiakes DJ; Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.
Am Heart J ; 140(4): 603-10, 2000 Oct.
Article in En | MEDLINE | ID: mdl-11011333
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Fab Fragments / Platelet Aggregation Inhibitors / Angioplasty, Balloon, Coronary / Platelet Glycoprotein GPIIb-IIIa Complex / Coronary Disease / Antibodies, Monoclonal Type of study: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Am Heart J Year: 2000 Document type: Article Affiliation country: Country of publication:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Fab Fragments / Platelet Aggregation Inhibitors / Angioplasty, Balloon, Coronary / Platelet Glycoprotein GPIIb-IIIa Complex / Coronary Disease / Antibodies, Monoclonal Type of study: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Am Heart J Year: 2000 Document type: Article Affiliation country: Country of publication: